Stay updated with breaking news from Biocon Biologic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Read more about Benchmarks end almost flat; Nifty holds 15,300 on Business Standard. Domestic benchmark indices ended almost flat after a volatile session on Tuesday. The Nifty managed to close above the 15,300 mark after slipping below that level in intraday. Selling in private banks and IT stocks negated strength in metal and PSU
Barometers further pared gains in early afternoon trade, led by weakness in IT and private banks. Metal, PSU banks and realty stocks were in demand. At 12:20 IST, the barometer index, the S&P BSE Sensex, rose 63.59 points or 0.12% at 52,217.72. The Nifty 50 index was up 31.30 points or 0.20% at 15,346. In the broader market, the S&P BSE Mid-Cap index rose 0.41% while the S&P BSE Small-Cap index gained 0.50%. The market breadth turned negative. On the BSE, 1,364 shares rose and 1,439 shares fell. A total of 154 shares were unchanged. Economy: India's exports grew by 6.16% to $27.45 billion in ...
Biocon Biologics reports topline of ₹769 crore in Q3 January 22, 2021 The subsidiary of Biocon Ltd raised raised $330 million in the quarter, says CEO Hamacher Biocon Biologics Limited, a subsidiary of Biocon Limited, has seen revenue growth in Q3 FY21 mainly driven by steady marketshare of products in the US and growth in key MoW markets including AFMET and India. “Through our partners, we continue to expand sales for rHI (recombinant human insulin) in key markets like Mexico and Malaysia, and Insulin Glargine in Algeria and Malaysia. We continue to be the leading player for biosimilar T...
Biopharmaceutical major Biocon Ltd has posted a nearly 19 per cent dip on a year-on-year (YoY) basis in its consolidated net profit at Rs 186.6 crore for the third quarter of FY21, owing to its generics business taking a hit along with headwinds across operational, regulatory and commercial functions. The third quarter of the last financial year had seen the Bengaluru-headquartered company post a net profit of Rs 230.3 crore. Biocon's consolidated revenue for Q3 of FY21 increased by 7.20 per cent at Rs 1878.9 crore as against Rs 1752.6 crore for the said quarter last year. The company's co...
Biocon Biologics gets Rs 555 crore capital injection from ADQ ANI | Updated: Jan 07, 2021 18:19 IST Bengaluru (Karnataka) [India], Jan 7 (ANI): Abu Dhabi-based ADQ will invest Rs 555 crore for 1.8 per cent minority stake in Biocon Biologics, valuing it at a post money valuation of 4.17 billion dollars (about Rs 30,482 crore). Post the completion of transaction, Biocon Ltd will hold 89.89 per cent stake in Biocon Biologics on a fully diluted basis. "This investment is an endorsement of the value that Biocon Biologics business has built as a fully integrate...